V Square Quantitative Management LLC Acquires Shares of 2,378 Labcorp Holdings Inc. $LH

V Square Quantitative Management LLC acquired a new stake in shares of Labcorp Holdings Inc. (NYSE:LH) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,378 shares of the medical research company’s stock, valued at approximately $597,000.

Several other institutional investors have also bought and sold shares of LH. Lazard Asset Management LLC lifted its position in Labcorp by 224.1% during the second quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock valued at $259,734,000 after purchasing an additional 684,153 shares during the last quarter. Victory Capital Management Inc. lifted its position in Labcorp by 20.0% during the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock valued at $756,878,000 after purchasing an additional 440,224 shares during the last quarter. Pacer Advisors Inc. lifted its position in Labcorp by 4,070.6% during the third quarter. Pacer Advisors Inc. now owns 305,746 shares of the medical research company’s stock valued at $87,767,000 after purchasing an additional 298,415 shares during the last quarter. Wellington Management Group LLP lifted its position in Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock valued at $604,488,000 after purchasing an additional 289,029 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Labcorp by 79.1% during the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock valued at $178,996,000 after purchasing an additional 275,454 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Insider Activity at Labcorp

In related news, CEO Adam H. Schechter sold 8,705 shares of Labcorp stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the sale, the chief executive officer owned 80,773 shares in the company, valued at $22,613,209.08. This trade represents a 9.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of Labcorp stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president owned 30,107 shares of the company’s stock, valued at $8,619,935.17. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 16,113 shares of company stock worth $4,547,450. Corporate insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the subject of several research reports. Piper Sandler increased their price objective on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. raised their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a report on Wednesday. Finally, Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and an average target price of $307.20.

Labcorp Price Performance

Labcorp stock opened at $261.35 on Friday. The firm has a 50-day moving average price of $274.39 and a 200-day moving average price of $268.80. The firm has a market capitalization of $21.54 billion, a PE ratio of 24.99, a price-to-earnings-growth ratio of 1.87 and a beta of 1.02. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities research analysts forecast that Labcorp Holdings Inc. will post 16.01 EPS for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.